Abstract 2105P
Background
Abemaciclib-induced diarrhea represents a major concern in clinical practice, as it can severely affect patients' quality of life and cause treatment discontinuation and dose modifications. Since growing evidence emphasize the role of microbiota in abnormal bowel clinical manifestations, a new class of natural molecules, called postbiotics, offers a potential option for managing abemaciclib-induced diarrhea.
Methods
We conducted a prospective, observational, single-arm study to evaluate the effect of the postbiotic food supplement “PostbiotiX-RestoreTM” on abemaciclib-induced diarrhea. We enrolled 36 hormone receptor-positive HER2-negative breast cancer (BC) patients at IRCCS Humanitas Research Hospital. The postbiotic was administered once daily from day -7 to the end of the first cycle of abemaciclib. From day-7 and until the end of the second cycle of abemaciclib, patients reported a daily questionnaire on bowel movements, concomitant medications, diet, and treatment discontinuation. Diarrhea was defined according to version 4.0 of the National Cancer Institute’s Common Terminology Criteria for Adverse Events. Incidence of diarrhea of any grade, its median duration and median time to diarrhea onset were assessed.
Results
An overall regularization of bowel movements in the first week of treatment with PostbioticX-RestoreTM alone was reported. Diarrhea events occurred in all patients, but predominantly G1 (87.1%) and G2 (12.3%), with a very low percentage of G3 (0.6%; all occurring during the second cycle, off postbiotic) and no G4 events. The median time to diarrhea onset was 4 days (IQR 1-41) with a median duration of G1, G2, and G3 events of 4 (IQR 1-17), 1 (IQR 1-5), and 1 (IQR 1-1) days, respectively. There was only one case of dose reduction (during the second cycle, off postbiotic) and no case of treatment withdrawal due to diarrhea.
Conclusions
Our results suggest a promising effect of PostbioticX-RestoreTM in the management of abemaciclib-induced diarrhea. Compared to pivotal trials on abemaciclib in BC patients, we observed a reduced severity and shorter duration of diarrhea.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06